Compass Wealth Management LLC Takes Position in Grifols, S.A. (NASDAQ:GRFS)

Compass Wealth Management LLC purchased a new position in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 76,116 shares of the biotechnology company's stock, valued at approximately $541,000.

Other hedge funds have also recently modified their holdings of the company. Sequoia Financial Advisors LLC raised its position in Grifols by 14.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock worth $186,000 after buying an additional 3,399 shares during the last quarter. Oppenheimer Asset Management Inc. increased its stake in shares of Grifols by 66.5% during the first quarter. Oppenheimer Asset Management Inc. now owns 60,063 shares of the biotechnology company's stock worth $427,000 after acquiring an additional 23,980 shares during the period. Hennion & Walsh Asset Management Inc. raised its holdings in Grifols by 20.3% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 266,005 shares of the biotechnology company's stock worth $1,891,000 after purchasing an additional 44,818 shares in the last quarter. NBC Securities Inc. raised its holdings in Grifols by 112,543.1% during the first quarter. NBC Securities Inc. now owns 57,448 shares of the biotechnology company's stock worth $408,000 after purchasing an additional 57,397 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Grifols by 426.1% in the first quarter. GAMMA Investing LLC now owns 26,087 shares of the biotechnology company's stock valued at $1,850,000 after purchasing an additional 21,128 shares during the period.

Analyst Ratings Changes

Several analysts have recently commented on GRFS shares. JPMorgan Chase & Co. raised their price target on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a report on Tuesday, June 17th. Wall Street Zen lowered shares of Grifols from a "strong-buy" rating to a "buy" rating in a research report on Sunday, June 29th.

Grifols Price Performance

GRFS traded down $0.07 on Friday, hitting $9.08. 191,164 shares of the company were exchanged, compared to its average volume of 1,119,538. Grifols, S.A. has a fifty-two week low of $6.19 and a fifty-two week high of $9.96. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.97 and a current ratio of 2.60. The firm has a market capitalization of $6.24 billion, a P/E ratio of 7.76, a price-to-earnings-growth ratio of 0.33 and a beta of 0.55. The business's fifty day moving average is $8.24 and its 200 day moving average is $7.70.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.